Dawn Svoronos - 09 Dec 2025 Form 4 Insider Report for Adverum Biotechnologies, Inc. (ADVM)

Reporting relationship: Director
Issuer ticker: ADVM
Reported as of: 09 Dec 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Dec 2025, 13:31:45 UTC
Prior SEC filing: 20 Jun 2025
Next SEC filing: 03 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Aneta Fergson, Attorney-in-Fact

Key filing fact

Dawn Svoronos filed Form 4 for Adverum Biotechnologies, Inc. (ADVM) on 10 Dec 2025.

Key facts

This page summarizes Dawn Svoronos's Form 4 filing for Adverum Biotechnologies, Inc. (ADVM).
7 reported transactions and 6 derivative rows are listed below.
Accepted by SEC: 10 Dec 2025, 13:31.

Change

Previous filing in this sequence was filed on 20 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001574579 Primary reporting owner

Svoronos Dawn

Relationship: Director
Address: C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY
Signature: /s/ Aneta Fergson, Attorney-in-Fact
Signature date: 10 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ADVM transaction

Common Stock

Disposition pursuant to a tender of shares in a change of control transaction

Transaction value
Shares: -5,000
Change %: -100%
Price
Shares after: 0
Date: 09 Dec 2025
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ADVM transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -4,500
Change %: -100%
Price
Shares after: 0
Date: 09 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4,500
Exercise price: $128.20
Footnotes: F3

ADVM transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -4,000
Change %: -100%
Price
Shares after: 0
Date: 09 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4,000
Exercise price: $37.00
Footnotes: F3

ADVM transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -4,000
Change %: -100%
Price
Shares after: 0
Date: 09 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4,000
Exercise price: $9.90
Footnotes: F3

ADVM transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -4,000
Change %: -100%
Price
Shares after: 0
Date: 09 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4,000
Exercise price: $15.60
Footnotes: F3

ADVM transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -10,520
Change %: -100%
Price
Shares after: 0
Date: 09 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,520
Exercise price: $7.32
Footnotes: F3

ADVM transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -10,450
Change %: -100%
Price
Shares after: 0
Date: 09 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,450
Exercise price: $2.32
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Dawn Svoronos is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 4 footnotes

Footnote F1

In connection with the terms of an Agreement and Plan of Merger, dated as of October 24, 2025 (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's direct wholly owned subsidiary, Flying Tigers Acquisition Corporation ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $3.56 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration"); plus (ii) one non-tradable contingent value right (each, a "CVR"), which represents the contractual right to receive up to two contingent cash payments of up to an aggregate of $8.91 per CVR, net to the stockholder in cash,

Footnote F2

(continued from footnote 1) without interest and less any applicable tax withholding, upon the achievement of both specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "CVR Agreement") with Computershare Inc. and its affiliate, Computershare Trust Company, N.A, as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of December 9, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time").

Footnote F3

Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time.

Footnote F4

Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option granted under a Company Equity Plan having an exercise price less than the Cash Consideration (each such option, a "Cash-Out Stock Option") that was outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, and in exchange for such cancellation, the holder of such Cash-Out Stock Option received (i) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting).